The prognosis of peritoneal spread from gastrointestinal cancer and subsequent malignant ascites is poor, and current medical treatments available are mostly ineffective. Targeted chemotherapy with intraperitoneal prodrug activation may be a beneficial new approach. L293 cells were genetically modified to express the cytochrome P450 enzyme 2B1 under the control of a cytomegalovirus immediate early promoter. This CYP2B1 enzyme converts ifosfamide to its active cytotoxic compounds. The cells are encapsulated in a cellulose sulfate formulation (Capcellt). Adult Balb/c mice were inoculated intraperitoneally with 1 Â 10 6 colon 26 cancer cells, previously transfected with GFP to emit a stable green fluorescence, by injection into the left lower abdominal quadrant. Two or five day's later animals were randomly subjected to either i.p. treatment with ifosfamide alone or ifosfamide combined with microencapsulated CYP2B1-expressing cells. Peritoneal tumor volume and tumor viability were assessed 10 days after tumor inoculation by means of fluorescence microscopy, spectroscopy and histology. Early i.p. treatment with ifosfamide and CYP2B1 cells resulted in a complete response. Treatment starting on day 5 and single-drug treatment with ifosfamide resulted in a partial response. These results suggest that targeted i.p. chemotherapy using a combination of a prodrug and its converting enzyme may be a successful treatment strategy for peritoneal spread from colorectal cancer.
Introduction
Peritoneal spread from gastrointestinal cancer is a severely debilitating condition and accounts for a substantial morbidity and mortality among cancer patients. 1, 2 The subsequent malignant ascites causes significant pain and discomfort thus dramatically reducing the quality of life in these patients. 3, 4 Despite continuous efforts to develop medical and surgical treatments, options are limited and most often palliative. 5 Targeted chemotherapy is a novel approach towards treatment of intraperitoneal cancer either by improving drug delivery from the site of application into the tumor cell 6 or by switching the site of the activation of a prodrug from the liver into the abdominal cavity, thereby enhancing the locoregional antitumor effect. Furthermore, regional application and activation of a prodrug allows a reduction of dosage of the prodrug and minimizes initial systemic distribution and thus systemic side effects of the drug. We describe here the proof of principle for the treatment of peritoneal carcinomatosis from colon cancer using low-dose ifosfamide together with CYP2B1 transfected, microencapsulated cells.
Oxazaphosphorines, for example, ifosfamide, are prodrugs that are metabolized into their active compounds by the liver cytochrome P450 system. The enzyme CYP2B1 converts ifosfamide into 4-OH-ifosfamide, which in turn results in the active compounds phosphoramide mustard and acrolein. 7 These active compounds have a very short half-life of a few minutes 8, 9 in plasma. Ifosfamide demonstrates antineoplastic activity against experimentally induced colon cancer [10] [11] [12] and it was suggested that it may be useful in the treatment of peritoneal cancer in humans as well. 13 In the case of peritoneal carcinomatosis the administration of ifosfamide-converting enzyme into the abdominal cavity provides activation of ifosfamide directly at the site of tumor development, thus circumventing activation of the prodrug in the liver. This principle has been used by transfection of human kidney cells with cytochrome P450 prior to establishing an experimental tumor and subsequent treatment with ifosfamide.
Microencapsulation of human embryonic kidney cells expressing a transfected ifosfamide-converting enzyme prevents the host immune system from attacking the transfected cells and allows implantation of non-HLAmatched cells into patients. 15 Previous studies have already demonstrated the effectiveness of targeted treatment with ifosfamide in combination with encapsulated cells producing ifosfamide-converting enzyme (Capcellt) in pancreatic cancer both in animals 16 and during a phase I study in patients. 17 Ifosfamide, converted to its active derivatives by Capcellt has been demonstrated to penetrate macroscopic tumor when applied in a distance of up to 10 mm in mice resulting in partial and complete tumor response as well. 18 The therapeutic regimen has also been successfully applied to spontaneously occurring breast carcinoma in dogs. 19 
Animals and methods

Animals and experimental design
Fifteen-week-old male Balb/c mice (Harlan-Winkelmann, Borchen, Germany) were used for the experiments, which were performed in accordance with German legislation on protection of animals, NIH recommendations for the use of laboratory animals 20 and the Interdisciplinary principles and guidelines for the use of animals in research, testing, and education. 21 The animals were kept in a temperature and humidity-controlled 12-h light cycle environment and had free access to water and standard pellet food during the entire experimental period. After intraperitoneal administration of syngenic colon 26 tumor cells, all animals were randomly placed in either treatment or control groups. Each group consisted of eight animals. Tumor growth was assessed 10 days after inoculation at laparotomy.
Cell culture and tumor cell inoculation
The murine colon tumor cell line colon 26 originally derived from Balb/c mice was transfected with the EGFPencoding expression vector pEGFP-N1 (Clontech, Heidelberg, Germany) as previously described. 22 We have demonstrated that EGFP fluorescence well correlates to tumor viability and will be effected by cell death only. 23 Cells were grown in DMEM-medium (Gibco BRL, Life Technologies, Scotland) supplemented with 10% fetal calf serum (FCS, PAN Biotechnologies GmbH, Germany) and antibiotics (1% penicillin-streptomycin, PAN Biotechnologies GmbH, Germany) and kept in an atmosphere of 100% humidity and 5% CO 2 at 371C. The cells were harvested after having reached confluency and were checked for viability using the Trypan blue exclusion test.
Metastatic peritoneal tumor growth was induced by intraperitoneal injection of 1x10 6 tumor cells suspended in 1 ml PBS into the left lower abdominal quadrant.
Intraperitoneal treatment
The prodrug ifosfamide (Holoxan s , Baxter Oncology, Frankfurt/Main, Germany) and microencapsulated cells (Capcellt; Bavarian Nordic, Martinsried, Germany) producing the cytochrome P450 subtype of ifosfamideconverting enzyme CYP2B1, which converts ifosfamide into 4-OH-ifosfamide, were used for intraperitoneal, targeted chemotherapy. The making, biological and pharmacological properties of this construct have been described elsewhere. 18, 24 In brief, human L293 cells were transfected with a pCDNA3 vector carrying the murine cytochrome P450 enzyme 2B1 under the control of a CMV early promoter. Cells were microencapsulated in sodium cellulose sulphate as the anion and poly-DADCMAC as cation using an Inotech device (Dottikon, Switzerland). Integrity of capsules was assessed microscopically. Cell viability was measured with the Life Death assay (Molecular probes). Enzymatic function was assessed using the restrain assay and a biological assay measuring the cell killing capacity. 16, 17, 24, 25 Microcapsules are 0.7 mm diameter on average incorporating 3 Â 10 5 cells/capsule. In a first set of experiments (A), a single dose of either ifosfamide 100 mg/kg body weight alone or in combination with 50 Capcells in 0.5 ml of saline was administered on day 2 or 5 after tumor inoculation. In a second set of experiments (B), 50 Capcells were administered on day 2 or 5 followed by a daily administration of ifosfamide on 5 consecutive days (days 2-6 or 5-9). Another two groups of animals received daily ifosfamide alone for 5 consecutive days (days 2-6 or 5-9). Both Capcellt and ifosfamide were injected into the left lower abdominal quadrant with a 21 G syringe.
Assessment of peritoneal tumor spread, tumor growth and response to treatment The animals were anesthetized by i.p. administration of xylazine hydrochloride 2.5-5 mg/kg (Rompun, Bayer AB, Leverkusen, Germany) and ketamine 100 mg/kg (Hostaket, Parke-Davis, Freiburg, Germany) and placed on a heated operation table (K Effenberger, Med. Tech. Gera¨tebau, Pfaffing, Germany) in a supine position. Laparotomy was performed by a standard midline abdominal incision. Intra abdominal tumor spread was documented using photographs and fluorescence microscopy and quantified using a modified Sugarbaker-index. This index originally employed to score clinical tumor in patients was defined to score number (n) and diameter of peritoneal tumor nodules in our model as follows: 0 ¼ no macroscopic tumor; 1 ¼ tumor nodules p2 mm; 2 ¼ tumor nodules 2-5 mm; 3 ¼ tumor nodules X5 mm. Total tumor volume in each mouse was calculated as the sum of volumes of all peritoneal tumor nodules found in each animal. Peritoneal cancer usually presented as half spherical nodules adjacent to the peritoneum, the serosal surface of organs and in the peripancreatic tissue. The volume 'V' of each tumor nodule was estimated as half of a spherical volume with a radius 'r' using Segner's method: 26 V ¼ Fluorescence microscopy GFP-transfected colon 26 tumor cells emit green light when excited with blue light. The fluorescence was used to identify the dissemination of tumor nodules in the abdominal cavity and assess the viability of peritoneal metastases by means of intravital microscopy using a modified Zeiss microscope (Axiotech, Carl Zeiss, Germany) as previously described. 23 Viable tumor nodules were characterized by a bright green fluorescence expressed by the GFP-transfected tumor cells (510 nm) when excited with blue light (488 nm) using fluorescence microscopy.
Spectrometry
Viability of peritoneal metastases was also assessed by spectrometry. Intraperitoneal administration of deltaaminolevulinic acid (ALA) results in tumor-specific accumulation of protoporphyrine IX (PpIX). When excited with light at a defined wavelength and viewed with the appropriate filter, viable tumor cells containing PpIX have a characteristic red fluorescence. 27 Intraperitoneal photosensitization was induced by peritoneal lavage with 1 ml of ALA 1.5% (ALA, Medac, Germany). Fluorescence illumination was subsequently performed using the D-Light system (Karl Storz, Germany). The system is based on a 300 W Xenon short arc lamp producing a specific blue light (380-440 nm) for excitation of protoporphyrine IX (PpIX) fluorescence. The excitation light of the D-Light system was transferred to the tissue via one branch of a bifurcated fiber bundle (Avantes, Germany). The common tip of the fiber was brought in contact with the lesion and the second branch of the fiber was connected to an optical multichannel analyzer (OMA, Avantes, Germany). Spectral analysis was performed using commercial software (SpectraWint, Avantes, Germany). Background signals were subtracted from the spectra and fluorescence intensities measured at the maximal emission wavelength of PpIX at 635 nm. From each tissue sample multiple spectral intensities were gained and averaged. The fluorescence of unaffected bowel serosa served as control.
Histology
Specimens from tumor nodules, adjacent tissue, small bowel, liver and pancreas were taken for frozen sectioning and paraffin histology with hematoxylin-eosin staining (H&E). Frozen tissue samples were collected in tissue glue (Tissue Tekt, Sakura, Torrance) and fixed in ice-cold isopentane (3-methyl-1-butan). Blocks were kept at À801C until frozen, sections of tissue samples were cut in 7 mm slices using a Leica Cryostat (Leica, Wetzlar, Germany). Vital tumor cells and nodules were identified by GFP-expression of colon 26 cancer cells using fluorescence microscopy. For HE histology 3 mm slices were deparaffinized with ethanol (99, 96 and 80%), stained for 10 min with hematoxylin, washed and counterstained with 0.1% eosin before being fixed in ethanol. Slides were embedded with Eukitt s (O Kindler, Freiburg, Germany).
In order to determine whether the treatment of the tumor cells in Balb/c mice resulted in an induction of apoptosis, samples were analyzed by TUNEL technology using the in situ Cell Death Detection Kit, Fluorescein (Roche Diagnostics Basel, Switzerland) according to the manufacturer's recommendations. In brief, cryostat sections (10 mm) were fixed in formaldehyde (4% in PBS, pH 7.4) for 20 min at room temperature. After washing with PBS for 30 min, tissues were permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate for 2 min on ice. After two additional washes with PBS, tissue sections were incubated in TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling) reaction mixture for 60 min at 371C in the dark. 28 Subsequently, tissue sections were counterstained with DAPI using a DAPI-containing mounting medium (Vectashield with DAPI, Vector Laboratories, Burlingame, CA). Fluorescein (excitation: 450-490 nm, blue; emission: 510-540 nm, green) and DAPI (excitation: 340-380 nm, UV; emission: about 460 nm, blue) fluorescence were documented with a Leica microscope and IM50 software. For positive controls, tissue sections were incubated with 3 U/ml DNase I (MBI Fermentas) for 10 min at room temperature after the permeabilization step. For negative controls, the enzyme solution was omitted in the labeling reaction. The proportion of tumor cells undergoing apoptosis was determined by a scientist unaware of the origin of the specimens by assessment of the number of apoptotic cells per high power field (HPF) in 10 HPF in each animal.
Statistical analysis
The proportion of tumor cells undergoing apoptosis and total volumes of tumor nodules found in each animal are presented as means7standard deviation (s.d.). Statistical analysis was meant to determine, if mean tumor volume in any of our experimental groups differed from tumor volume in controls and all other treatment groups. We compared mean tumor volumes in each treatment group versus. controls and other groups by one-way analysis of variance (ANOVA). If ANOVA indicated a significant difference between groups, pair wise multiple comparison of all means and post hoc testing using Tukey's method were employed to determine significant differences between groups and controls. Differences were considered significant if Po0.05. SPSS 10.0.7 software (SPSS Inc. 1989-1999) was used for statistical analysis.
Results
Tumor growth and response to treatment
Macroscopic peritoneal cancer developed in all animals subjected to intraperitoneal administration of colon 26 cancer cells (Figure 1 ). The dissemination of colon 26 carcinoma within the peritoneal cavity was described by a modified Sugarbaker-index (Table 1) . At 10 days after tumor cell administration untreated animals (controls) had developed macroscopic tumor consisting of several tumor nodules of various sizes (median 14, range 10-18). Most tumor nodules were p2 mm in diameter (median 6, range 3-10). Larger nodules were less frequent (2-5 mm: median 3.5, range 2-6; X5 mm: median 4.5, range 2-6). The mean peritoneal tumor volume in this group of untreated animals was 87.75711.32 mm 3 (Figure 2a  and b) .
Peritoneal treatment resulted in an apparent reduction of macroscopic peritoneal tumor with less tumor nodules overall and fewer nodules with a size of 2-5 mm and X5 mm, respectively. Assessment of mean tumor volume showed corresponding results. Early i.p. treatment with ifosfamide þ Capcellt on day 2 resulted in a significant tumor reduction (tumor volume: 9.8679.60 mm 3 The (Figure 2b) . None of the animals developed tumor at the site of injection in the left lower abdominal quadrant.
Complete remission was defined as absent GFP tumor fluorescence on microscopy and spectroscopy and was confirmed using histology in all animals subjected to treatment with Capcellt þ ifosfamide on days 2-6. Partial response was indicated by a significant reduction (450%) of tumor volume in the other treatment groups.
The characteristic fluorescence emitted by GFP (Figure 3) and PpIX (Figure 4 ) was markedly decreased in these animals. Both, the expression of GFP and the accumulation of ALA by the tumor cell served as indicators of viability of peritoneal metastases. The expression of GFP results from prior transfection of the pEGFP-N1 vector, while intraperitoneal administration Figure 2 Tumor volume in response to i.p. treatment is represented by vertical bars (mean7s.d.). Groups were compared by ANOVA and multiple comparisons of means using post hoc Tukey's test in order to detect significant differences between groups. Significant differences of one group versus controls (no treatment) and versus other treatment groups are indicated (*). of ALA is necessary for a tumor-specific accumulation of PpIX. When excited with light at a defined wavelength and viewed with the appropriate filter, viable tumor cells containing PpIX have a characteristic red fluorescence. However, there were no marked differences in protoporphyrine-fluorescence between treatment groups with complete and incomplete cytoreduction (ifosfamide alone on days 2-6 and 5-9, and Capcellt þ ifosfamide on days 2-6 and 5-9). GFP fluorescence was not quantified in these animals.
In comparison to control animals without treatment, the proportion of cancer cells undergoing apoptosis increased significantly to more than 80% in animals subjected to i.p. treatment with Capcellt þ ifosfamide s . There was no increase of apoptosis when ifosfamide alone was given for 2 or 5 days or 2-6 or 5-9 days after tumor inocculation ( Table 2 ). In control animals with untreated tumor the spontaneous proportion of apoptotic cancer cells was 14% ( Figure 5 ).
Discussion
Peritoneal carcinomatosis and subsequent malignant ascites represent severe complications of advanced metastatic spread in gastric and colorectal cancer 1, 2, 29, 30 as well as in other intra abdominal malignancies. 31, 32 Treatment options are few. Although local instillation of cytotoxic drugs is possible, it has not been widely applied due to the lack of significant effectiveness. 33 Intraperitoneal hyperthermic chemotherapy, both as an adjuvant and for palliation following surgical cytoreduction may have some impact on patient's prognosis. 4, 30 We describe here the application of ifosfamide in combination with CYP2B1 expressing, microencapsulated cells as a proof of principle for the treatment of experimental peritoneal carcinomatosis. While a single dose of ifosfamide þ Capcell s t already resulted in a significant reduction in tumor mass, administration of ifosfamide þ Capcell s for a prolonged period resulted in complete tumor remission in some animals (treatment on days 2-6) and a partial response in the remainder (treatment on days [5] [6] [7] [8] [9] . No side effects of this chemotherapy could be observed. The application of ifosfamide alone, without the Capcellt, was less effective. The antitumoral effect of ifosfamide þ Capcell s , measured by tunnel assay, is mainly apoptotic, as demonstrated before. 16, 34 In addition, necrosis may enhance the antitumoral effect of Capcell s treatment. 35 The liver has the largest pool of the CYP2B1 of cytochrome P450. However, as demonstrated before, 24 the availability of a local conversion site such as the Capcellt containing CYP2B1-expressing cells results in an added peak of activated compounds such as 4-OHifosfamide. This is of particular importance since the terminal half-lives of active metabolites are less than 20 min in plasma and total clearance is less than 20 ml/ min. 8, 9, 36 In a similar animal model, gene transfer of CYP2B1 to tumor cells prior to the establishment in vivo and subsequent treatment with cyclophosphamide resulted in a significant antitumor effect. 14, 37 These results are supported by our model of CYP2B1-transfected cells brought into the immediate vicinity of the tumor cells. A further improvement may be the additional expression of Figure 4 Intraperitoneal administration of delta-aminolevulinic acid (ALA) results in tumor-specific accumulation of PpIX. Intraperitoneal treatment resulted in a marked decrease in intensity of the characteristic red fluorescence as compared to untreated controls. The differences between treatment groups were not significant. Fluorescence in animals with complete tumor remission resembles fluorescence of normal peritoneal serosa. I.p. treatment with ifosfamide+Capcell s caused a significant induction of apoptosis (*) without differences between groups. Treatment with ifosfamide alone did not increase tumor cell apoptosis when compared with untreated controls. cytochrome reductase thus enhancing the effect of the active metabolites. 38 This concept has recently been taken even further by transfection of a retrovirus containing both a cytochrome P450 (CYP2B6) together with the cytochrome reductase P450R and an E1b gene-deleted adenovirus Onyx-017. The use of a tumor-selective, replicating adenovirus to promote the spread of replication-defective gene therapy vectors, such as Adeno-P450, may increase the therapeutic potential of adenoviral delivery systems, and may increase cytochrome P450 activity and enhance tumor selectivity. 39 The present paper deals with two aspects of experimental oncology, tumor imaging and treatment. First, bioimaging of fluorescent tumor cells may help to identify invasive 40 or metastatic tumor. 41 Second, bioimaging may indicate viability of invasive cancer and metastasis in vivo. Furthermore, assessment of the intensity of a characteristic fluorescence emitted by a tumor may help to estimate the portion of viable tumor tissue in animal experiments 42 as utilized in this study. By using colon 26 cancer cells transfected with a commercial GFP vector in Balb/c mice, we have established a syngenic tumor model of fluorescent metastatic peritoneal colon cancer. In this model, tumor cell dissemination and viability of tumor cells can be assessed by means of intravital fluorescence microscopy on laparotomy. Alternative methods of detecting and determining tumor cells and their viability are spectroscopy and spectrometry. These measures can be applied on laparoscopy. After having metabolized ALA into PpIX, tumor cells emit a characteristic red fluorescence, which can be detected using spectroscopy. Its intensity as an indicator of tumor viability can also be quantified by spectrometry. 43 Local photosensitization by intraperitoneal administration of ALA has been shown to be more reliable and effective in producing tumor fluorescence than systemic (i.v.) photosensitization. 27 In summary, by using GFP-transfected colon 26 tumor cells in mice we established a well-reproducible animal model of metastatic peritoneal cancer. Fluorescent imaging of GFP-transfected tumor was used to demonstrate tumor distribution in the peritoneal cavity and to estimate tumor growth and tumor response to treatment in this model. The application of microcapsules and ifosfamide into the peritoneal cavity is a safe and welltolerated procedure in this animal model and may help to target chemotherapeutic agents specifically to metastatic peritoneal cancer. 
